Abstract

REVIEW ON FDA APPROVED NEW DRUGS ON ONCOLOGY

Dr. Pramod Kumar*, K. Rooha and K. Pragnya Dutt

ABSTRACT

Cancer remains the second leading cause of death globally. The number of new medicines targeting cancer has grown impressively since the 1990s. On average, ten new drugs are introduced each year. Such growth has partly been achieved by emphasizing biologics and orphan indications, which account for one-quarter and one-half of new oncology drugs, respectively.The new drugs approved by FDA on oncology were Erleada (apalutamide) and Lutathera (lutetium Lu 177 dotatate).The objective was to compare FDA approved new drugs for Oncology. Erleada is the first FDA approved therapy to treat patients with Non-metastatic castration-resistant prostate cancer. Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The study compared the characteristics of new human drugs approved by the FDA. The study included the mechanism, doses, Route of administration and other characters of the drug. Many of these drugs contain the active moiety which were not previously approved by the FDA, either as a single ingredient drug or as part of a combination product; these products frequently provide important therapies for patient .The availability of the new drugs and biological products often means new treatment options for patients and for advances in health care.

Keywords: Cancer, Erleada, Lutathera, Therapy.